Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy

Inclusion Criteria

\- Patients with a recommendation for antineoplastic therapy including at least four administrations of an anthracycline

Exclusion Criteria

* Inability to provide informed consent
* Prior administration of an anthracycline
* Administration of cardiotoxic drugs within the last six months, such as:
* High-dose cyclophosphamide (\>1,000 mg/m² or \>10 mg/kg)
* HER2 inhibitors
* VEGF inhibitors
* BCR-ABL inhibitors
* BRAF inhibitors
* MEK inhibitors
* Immune checkpoint inhibitors (CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors)
* Planned invasive cardiac intervention during the study period
* Cardiac involvement of an underlying disease, e.g. amyloidosis
* Treatment with fewer than four administrations of anthracyclines
* Treatment with a liposomal anthracycline formulation
* Treatment in which anthracyclines are not administered in every chemotherapy cycle
* Thoracic radiation involving the heart prior to anthracycline administration
* Participation in another clinical study concurrently or within the last three months
* Renal impairment with a GFR \< 30 ml/min/1.73 m²
* Patients in the perioperative phase of liver transplantation
* Contraindications to cardiac magnetic resonance imaging, such as metallic implants (e.g. cardiac pacemaker)
* Pregnancy or breastfeeding
* Hypersensitivity or intolerance to gadolinium-based contrast agents
* Vulnerable populations (individuals unable to protect their own interests, prisoners)